Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute and Dana-Farber/Boston Children's Cancer and Blood Disorders Center showcased their advances at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, in December of 2016.
As the premier conference in the field, the ASH Annual Meeting attracts more than 20,000 experts who share their advances in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, as well as other blood disorders.
Attendees visited our Dana-Farber and Dana-Farber/Boston Children’s booths to connect with our adult and pediatric physicians and scientists – and learn more about our discoveries, innovations, and clinical trials.
Many faculty from Dana-Farber’s Center for Hematologic Oncology presented advances at ASH 2016.View the schedule of select presentations.
Join the Twitter conversation at #ASH16Follow us on LinkedIn
Visitors to Dana-Farber's booth met one-on-one with specialists from our Adult Hematologic Malignancies program. Faculty members were available to answer questions, discuss a challenging case, or discuss advances covered at ASH:
Saturday, December 3Jacqueline Garcia, MD
Expert in Acute Myeloid Leukemia
Saturday, December 3Robert Soiffer, MD
Expert in Stem Cell Transplantation
Sunday, December 4Jorge Castillo, MD
Expert in Waldenström's Macroglobulinemia
Sunday, December 4Caron Jacobson, MD
Expert in Lymphoma
Monday, December 5Jacob Laubach, MD
Expert in Multiple Myeloma
Mutations in lymphoma patients undergoing transplants raise risk of second cancers
A significant percentage of lymphoma patients undergoing transplants with their own blood stem cells carry acquired genetic mutations that increase their risks of developing second hematologic cancers and dying from other causes, according to a study from Dana-Farber researchers.
Children with Down syndrome and acute lymphoblastic leukemia fare as well as other children treated on Dana-Farber ALL Consortium protocols
Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber ALL Consortium Protocols.
Immunotherapy agent yields full and partial remissions in patients with aggressive non-Hodgkin lymphomas, study finds
An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with two rare, aggressive forms of non-Hodgkin lymphoma, results from Dana-Farber researchers show.
Early treatment may prevent progression to multiple myeloma
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk “smoldering” multiple myeloma to the full-blown disease, according to researchers from Dana-Farber.
Drug combination yields encouraging results in patients with relapsed forms of leukemia or lymphoma in early stage study
A study led by Dana-Farber researchers shows a combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia or mantle cell lymphoma.
Genetic classification offers guide to stem cell transplantation for patients with myelodysplastic syndrome
A blood test can indicate whether some patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant and, if so, whether the transplant should involve high or moderate doses of chemotherapy and/or radiation therapy, according to a study by scientists at Dana-Farber.
Select 2016 publications by Dana-Farber faculty
On December 7, conference attendees heard Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber’s Jerome Lipper Multiple Myeloma Center and the R.J. Corman professor of Medicine at Harvard Medical School, as he presented ASH’s 2015 Ernest Beutler Lecture with Alfred Goldberg, PhD. The lecture topic was, "Understanding the Proteasome: from Protein Degradation to Disease Therapy."
At this year’s meeting, many renowned Dana-Farber and Dana-Farber/Boston Children’s experts in hematological malignancies and hematology shared their discoveries, innovations, and insights from their adult and pediatric research and clinical practice.
Download these rosters of select Dana-Farber and Dana-Farber/Boston Children’s conference speakers:
ASH 2015 Dana-Farber SpeakersASH 2015 Dana-Farber/Boston Children's Speakers
At Dana-Farber and Dana-Farber/Boston Children’s, we’re proud of our leadership role – at the Annual Meeting, and in the Society itself. Dana-Farber/Boston Children’s pediatric oncologist David Williams, MD, is 2015 ASH president. And Dana-Farber medical oncologist Kenneth Anderson, MD, is 2015 ASH vice president and 2016 ASH president-elect.
ASCO POST Newsreel: 'Dana-Farber's Richard M. Stone, MD, discusses the RATIFY trial, an international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly disagnosed acute myeloid leukemia with FLT3 mutations'
OncLive: 'Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML'
OncologyNurseAdvisor: 'Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL'
Medscape: 'Rituximab + Chemo: New Standard of Care for BCP-ALL?'
Cancer Therapy Advisor: 'Nidostaurin Prolongs Survival in Patients with Newly Diagnosed AML'
Medscape: 'Midostaurin in AML: First Targeted Agent Improves Survival'
Dana-Farber experts presented exciting new research findings at the 2015 conference. Presentations included: